GlassScriptPhysician profile
Robert L Henderson
NPI 1306833041
$25,397.07
in general payments reported to CMS, 2019-2025
40 companies · $4,672 in 2025
The $4,672 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,516 · 2021: $2,749 · 2022: $3,040 · 2023: $5,462 · 2024: $6,492 · 2025: $4,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,402 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,055.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,402.26 |
| Education | $167.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,024.07 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,455.69 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,344.20 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,316.71 | 2019-2025 | Ilumya, Odomzo, Absorica Ld |
| Allergan, INC. | $1,100.85 | 2019-2022 | |
| Lilly USA, LLC | $1,086.19 | 2019-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $1,079.62 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $955.08 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $893.06 | 2019-2025 | |
| Incyte Corporation | $818.33 | 2021-2025 | Opzelura, Pemazyre |
| Leo Pharma INC. | $773.99 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $724.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $614.65 | 2022-2025 | Sotyktu |
| Amgen INC. | $551.68 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $441.47 | 2022-2024 | Vtama |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.